+

WO2002053184A3 - Utilisations de composes polycationiques - Google Patents

Utilisations de composes polycationiques Download PDF

Info

Publication number
WO2002053184A3
WO2002053184A3 PCT/EP2002/000062 EP0200062W WO02053184A3 WO 2002053184 A3 WO2002053184 A3 WO 2002053184A3 EP 0200062 W EP0200062 W EP 0200062W WO 02053184 A3 WO02053184 A3 WO 02053184A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine adjuvants
polycationic compounds
polycationic
compounds
vaccine
Prior art date
Application number
PCT/EP2002/000062
Other languages
English (en)
Other versions
WO2002053184A2 (fr
Inventor
Karen Lingnau
Frank Mattner
Walter Schmidt
Max Birnstiel
Michael Buschle
Original Assignee
Intercell Biomedizinische Forschungs & Entwicklungs Gmbh
Cistem Biotechnologies Gmbh
Karen Lingnau
Frank Mattner
Walter Schmidt
Max Birnstiel
Michael Buschle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2001/000087 external-priority patent/WO2001054720A1/fr
Application filed by Intercell Biomedizinische Forschungs & Entwicklungs Gmbh, Cistem Biotechnologies Gmbh, Karen Lingnau, Frank Mattner, Walter Schmidt, Max Birnstiel, Michael Buschle filed Critical Intercell Biomedizinische Forschungs & Entwicklungs Gmbh
Priority to EP02700194.0A priority Critical patent/EP1347775B1/fr
Priority to CA002433794A priority patent/CA2433794A1/fr
Priority to JP2002554133A priority patent/JP2004519452A/ja
Priority to US10/250,953 priority patent/US7244438B2/en
Publication of WO2002053184A2 publication Critical patent/WO2002053184A2/fr
Publication of WO2002053184A3 publication Critical patent/WO2002053184A3/fr
Priority to US11/757,007 priority patent/US20080025996A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé polycationique pour la préparation d'un médicament à libération in vivo retardée.
PCT/EP2002/000062 2001-01-05 2002-01-07 Utilisations de composes polycationiques WO2002053184A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02700194.0A EP1347775B1 (fr) 2001-01-05 2002-01-07 Utilisation de substances polycationiques en tant qu'adjuvants pour vaccins
CA002433794A CA2433794A1 (fr) 2001-01-05 2002-01-07 Utilisations de composes polycationiques
JP2002554133A JP2004519452A (ja) 2001-01-05 2002-01-07 ポリカチオン性化合物の用途
US10/250,953 US7244438B2 (en) 2001-01-05 2002-01-07 Uses for polycationic compounds
US11/757,007 US20080025996A1 (en) 2001-01-05 2007-06-01 Methods and Compositions Comprising Polycationic Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP01/00087 2001-01-05
PCT/EP2001/000087 WO2001054720A1 (fr) 2000-01-28 2001-01-05 Composition pharmaceutique pour immunomodulation et preparation de vaccins comprenant un antigene, un oligodesoxyribonucleotide immunogene et polymere polycationique sous forme d'adjuvants
AT6722001 2001-04-25
ATA672/2001 2001-04-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/757,007 Division US20080025996A1 (en) 2001-01-05 2007-06-01 Methods and Compositions Comprising Polycationic Compounds

Publications (2)

Publication Number Publication Date
WO2002053184A2 WO2002053184A2 (fr) 2002-07-11
WO2002053184A3 true WO2002053184A3 (fr) 2002-09-19

Family

ID=25608382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000062 WO2002053184A2 (fr) 2001-01-05 2002-01-07 Utilisations de composes polycationiques

Country Status (4)

Country Link
EP (1) EP1347775B1 (fr)
JP (1) JP2004519452A (fr)
CA (1) CA2433794A1 (fr)
WO (1) WO2002053184A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053184A2 (fr) 2001-01-05 2002-07-11 Intercell Ag Utilisations de composes polycationiques
EP1608402B1 (fr) 2003-03-24 2010-10-20 Intercell AG Vaccins ameliores
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
KR101586200B1 (ko) * 2014-12-31 2016-01-18 성균관대학교산학협력단 면역자극 조성물, 이의 제조 방법, 및 이를 포함하는 면역요법 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB744988A (en) * 1952-01-31 1956-02-15 Allen & Hanburys Ltd Improvements in preparations of insulin
WO1991004052A1 (fr) * 1989-09-22 1991-04-04 Peptide Technology Ltd. Vaccins
WO1997030721A1 (fr) * 1996-02-24 1997-08-28 Boehringer Ingelheim International Gmbh Composition pharmaceutique pour l'immunomodulation a base de peptides et d'adjuvants
WO2000041679A1 (fr) * 1999-01-13 2000-07-20 Johns Hopkins University School Of Medicine Immunisation genetique avec administration conjointe d'acide nucleique et de cytokines
WO2000062800A2 (fr) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Vaccins
WO2001024822A2 (fr) * 1999-10-01 2001-04-12 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene
WO2001093905A1 (fr) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Oligonucleotides synthetiques immunostimulatoires
WO2002032451A1 (fr) * 2000-10-18 2002-04-25 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Composition de vaccin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503700A (ja) * 1991-01-03 1995-04-20 アルカーメス　コントロールド　セラピューティックス，　インコーポレイテッド カチオン生体ポリマーによるタンパク質の安定化
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
WO2002053184A2 (fr) 2001-01-05 2002-07-11 Intercell Ag Utilisations de composes polycationiques

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB744988A (en) * 1952-01-31 1956-02-15 Allen & Hanburys Ltd Improvements in preparations of insulin
WO1991004052A1 (fr) * 1989-09-22 1991-04-04 Peptide Technology Ltd. Vaccins
WO1997030721A1 (fr) * 1996-02-24 1997-08-28 Boehringer Ingelheim International Gmbh Composition pharmaceutique pour l'immunomodulation a base de peptides et d'adjuvants
WO2000041679A1 (fr) * 1999-01-13 2000-07-20 Johns Hopkins University School Of Medicine Immunisation genetique avec administration conjointe d'acide nucleique et de cytokines
WO2000062800A2 (fr) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Vaccins
WO2001024822A2 (fr) * 1999-10-01 2001-04-12 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene
WO2001093905A1 (fr) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Oligonucleotides synthetiques immunostimulatoires
WO2002032451A1 (fr) * 2000-10-18 2002-04-25 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Composition de vaccin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHMIDT W ET AL: "Cell-free tumor antigen peptide-based cancer vaccines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, April 1997 (1997-04-01), pages 3262 - 3267, XP002168512, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2433794A1 (fr) 2002-07-11
JP2004519452A (ja) 2004-07-02
WO2002053184A2 (fr) 2002-07-11
EP1347775B1 (fr) 2016-11-30
EP1347775A2 (fr) 2003-10-01

Similar Documents

Publication Publication Date Title
USD580059S1 (en) Fastening device for dental prostheses
WO2002080965A3 (fr) Composition vaccinale
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
WO2003037860A3 (fr) Analogues de purine presentant une activite inhibitrice de hsp90
WO2002013857A8 (fr) Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
IL175373A0 (en) The use of anti biotics as vaccine adjuvants
WO2009095226A3 (fr) Acides nucléiques de formule (i) (n<sb>u</sb>g<sb>l</sb>x<sb>m</sb>g<sb>n</sb>n<sb>v</sb>)<sb>a</sb> et leurs dérivés sous forme d'immunostimulant/adjuvant
WO2007146248A3 (fr) Préparations de laquinimod stables
WO2006085983A3 (fr) Adjuvants viraux
HRPK20040323B3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
WO2003014079A8 (fr) Polymorphe stable de flibanserine, procede de preparation associe et utilisation dudit polymorphe dans la preparation de medicaments
WO2004071374A3 (fr) Compositions pharmaceutiques d'administration orale une fois par jour
AU2002353417A1 (en) Adjuvanted antigenic meningococcal compositions
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2002222748A1 (en) Novel use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
AU2003282498A1 (en) Hiv vaccine formulations
AU2002210407A1 (en) Therapeutic vaccine formulations containing chitosan
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2002053184A3 (fr) Utilisations de composes polycationiques
AU2001278680A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the activeingredient
HUP0303938A3 (en) Use of rare earth compounds for the preparation of pharmaceutical compositions for the prevention of kidney stone disease
AU2001280208A1 (en) Vaccine preparation containing fatty acid as component
WO2002066048A8 (fr) Modification cristalline d'un depsipeptide cyclique presentant une efficacite amelioree

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002233302

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10250953

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2433794

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002554133

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2002700194

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002700194

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002700194

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载